A detailed history of Price T Rowe Associates Inc transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,959,088 shares of PLRX stock, worth $51 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,959,088
Previous 3,785,916 4.57%
Holding current value
$51 Million
Previous $68.6 Million 13.96%
% of portfolio
0.01%
Previous 0.01%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$14.14 - $19.59 $2.45 Million - $3.39 Million
173,172 Added 4.57%
3,959,088 $59 Million
Q4 2023

Feb 14, 2024

BUY
$12.85 - $19.15 $5.58 Million - $8.32 Million
434,429 Added 12.96%
3,785,916 $68.6 Million
Q3 2023

Nov 14, 2023

BUY
$14.58 - $20.15 $5.55 Million - $7.67 Million
380,554 Added 12.81%
3,351,487 $58.1 Million
Q2 2023

Aug 14, 2023

BUY
$18.12 - $30.56 $15.7 Million - $26.4 Million
864,689 Added 41.05%
2,970,933 $53.8 Million
Q1 2023

May 15, 2023

BUY
$18.73 - $36.26 $16.9 Million - $32.7 Million
900,510 Added 74.69%
2,106,244 $56 Million
Q4 2022

Feb 14, 2023

SELL
$17.0 - $25.43 $443,870 - $663,977
-26,110 Reduced 2.12%
1,205,734 $23.3 Million
Q3 2022

Nov 14, 2022

BUY
$7.67 - $24.23 $9.45 Million - $29.8 Million
1,231,844 New
1,231,844 $25.7 Million
Q3 2021

Nov 15, 2021

SELL
$16.48 - $28.98 $3.47 Million - $6.11 Million
-210,678 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$28.05 - $37.69 $97,585 - $131,123
-3,479 Reduced 1.62%
210,678 $6.14 Million
Q1 2021

May 17, 2021

BUY
$24.52 - $40.23 $5.25 Million - $8.62 Million
214,157 New
214,157 $8.42 Million

Others Institutions Holding PLRX

About PLIANT THERAPEUTICS, INC.


  • Ticker PLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,682,000
  • Market Cap $627M
  • Description
  • Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...
More about PLRX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.